Key Takeaways
- Aimei Health Technology Co., Ltd (Nasdaq: AFJK) received a Nasdaq deficiency notice on April 17, 2026 for missing the March 31, 2026 deadline to file its Form 10‑K for fiscal year 2025.
- The notice does not immediately affect trading; the company has 60 calendar days to file the report or submit a compliance plan, with a possible extension up to 180 days if the plan is accepted.
- If Nasdaq rejects the plan, Aimei may appeal to a Nasdaq hearings panel; continued non‑compliance could eventually lead to delisting.
- The company states it is working diligently to complete and file the Annual Report and expects to regain compliance.
- As a blank‑check (SPAC) entity incorporated in the Cayman Islands, Aimei’s purpose is to merge with a healthcare‑innovation‑focused target, though it is not limited to any specific industry or region.
- The press release includes standard forward‑looking‑statements disclaimer and provides investor‑contact information.
Notice of Nasdaq Deficiency
On April 17, 2026, Aimei Health Technology Co., Ltd received a formal notice from the Listing Qualifications Department of Nasdaq indicating that the company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to its delayed filing of the Annual Report on Form 10‑K for the fiscal year ended December 31, 2025. The report was due March 31, 2026, and the company had previously filed a Notification of Late Filing on Form 12b‑25 with the SEC on April 1, 2026. The notice serves as a procedural alert rather than an immediate trading suspension.
Immediate Impact on Trading
Although the notice signals a compliance shortfall, Nasdaq clarified that it has no immediate effect on the listing or trading of Aimei’s securities. Shares will continue to be bought and sold on the exchange while the company works to remedy the deficiency. This interim period allows investors to maintain their positions without fear of an abrupt halt in market activity, provided the company meets the forthcoming deadlines.
Compliance Timeline and Options
Under Nasdaq rules, Aimei has 60 calendar days from the date of the notice—until roughly mid‑June 2026—to either file the overdue Annual Report or submit a detailed plan outlining how it will regain compliance. If Nasdaq accepts such a plan, the company may be granted up to 180 calendar days from the original March 31, 2026 due date (approximately late September 2026) to complete the filing. Should Nasdaq reject the plan, Aimei retains the right to appeal the decision to a Nasdaq hearings panel, which would review the merits of the case and potentially grant further relief.
Company’s remedial actions
Aimei’s management emphasized that it is “working diligently to complete and file the Annual Report” and expressed confidence that it will regain compliance with the Listing Rule within the allowed timeframe. The statement suggests that internal audit, accounting, and legal teams are mobilizing to finalize the required disclosures, financial statements, and internal control assessments that constitute a Form 10‑K. While no specific completion date was provided, the tone indicates proactive efforts to avoid any escalation toward delisting.
Overview of Aimei Health Technology Co., Ltd
Aimei Health Technology Co., Ltd is a blank‑check company—commonly known as a special purpose acquisition company (SPAC)—incorporated as an exempted company with limited liability in the Cayman Islands. Its sole purpose is to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more operating businesses. Although the company’s charter does not restrict it to a particular sector, management has disclosed an intention to pursue targets focused on healthcare innovation, reflecting a strategic interest in medical technology, biopharma, digital health, or related fields.
SPAC Structure and Market Context
As a SPAC, Aimei raised capital through its initial public offering with the promise of using those funds to acquire an operating business within a prescribed timeframe—typically 18 to 24 months. The blank‑check vehicle provides investors with a shell entity that can be paired with a private company seeking public market access without undergoing a traditional IPO process. The healthcare focus aligns with current market trends where investors seek exposure to innovative therapies, telemedicine platforms, and health‑data analytics, though the company’s flexibility permits it to consider opportunities beyond that sector if advantageous.
Forward‑Looking Statements Disclaimer
The press release includes the customary forward‑looking‑statements caution, noting that any statements about future expectations, plans, or projections are based on management’s current assumptions and involve inherent risks and uncertainties. Actual outcomes may differ materially due to factors such as delays in completing the Annual Report, challenges in identifying a suitable acquisition target, regulatory hurdles, or shifts in market conditions. Aimei expressly states that it does not undertake to update these statements except as required by applicable securities law.
Investor and Media Contact Information
For further inquiries, the company provides contact details for its investor relations office: Aimei Health Technology Co., Ltd, 10 East 53rd Street, Suite 3001, New York, NY 10022, attention to Junheng Xie. Interested parties may reach out via email at [email protected]. This information enables shareholders, analysts, and journalists to obtain clarification on the filing status, upcoming milestones, or any other matters related to the Nasdaq notice and the company’s broader strategic initiatives.